![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Lonza is hosting a free 60-minute webinar on 24 October 2017, titled “Challenges and Strategies for Paperless Product Release – Bringing the Pieces Together.”
In a regulated manufacturing environment, production and quality tend to work in information “silos,” which creates challenges when managing a product release and often has associated costs. These “silos” can also have an impact on the ability to improve quality over time.
During the webinar strategies will be discussed to:
Reduce the cost, complexity and time of batch record review and approval for product release
Deliver simple, straight-forward analytics providing insight across production and quality disciplines so that these departments can share meaningful information
Create highly configurable workflows that make the end-to-end process paperless, with a focus on end quality and efficiency
Manage open systems with standard interfaces that comply with data integrity expectations
Session Date: Tuesday, 24 October 2017
Session 1: 8 AM EDT (New York) / 2 PM CET (Berlin)
or
Session 2: 11 AM PDT (Los Angeles) / 2 PM EDT (New York)
Speaker: Mike Goetter, Director of Informatics, Lonza Bioscience Solutions
Anyone interested in attending the webinar can register here.
MODA™ is a comprehensive platform for environmental, utility and product monitoring, combining automated scheduling, workflows, mobile data acquisition, device integration, and visual analytics. It eliminates paper-based monitoring and testing that can be expensive, error-prone, time and labor-intensive, therefore reducing timelines enhancing data integrity and potentially saving clients QC costs.
Further information can be found on the MODA product page. Alternatively, by registering interest in the webinar, participants unable to attend will receive a link once it is available to view “on demand” via the Lonza website.
More information about Lonza’s upcoming webinars is available on the following website: www.lonza.com/researchwebinars
About Lonza
Following the closing of the Capsugel acquisition, Lonza further strengthened its position as one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. Lonza harnesses science and technology to create products that support safer and healthier living and that enhance the overall quality of life.
An integrated solutions provider serving the healthcare continuum, Lonza offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. In addition to drinking water sanitizers, nutraceuticals, antidandruff agents and other personal care ingredients, the company provides agricultural products, advanced coatings and composites and microbial control solutions that combat dangerous viruses, bacteria and other pathogens.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide. Further information can be found at www.lonza.com
Lonza Contact Information
Lonza Cologne GmbH
Manager Marketing Communications
Petra Haberkamm
Tel +49 221 991990
petra.haberkamm@lonza.com
Lonza Group Ltd
Head External Communications
Constance Ward
Tel +41 61 316 8840
constance.ward@lonza.com
Additional Information and Disclaimer
Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.
Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.
